ID #967 PNOC031: An International Trial for Embryonal Tumor with Multilayered Rosettes (ETMR)
Derek Hanson, Susan Chi, Katja von Hoff, Barry Pizer, Marcel Kool, Mariella Filbin, Johannes Gojo, Niels Franke, Sarita Depani, Jordan Hansford, Girish Dhall, Annette Molinaro, Michael Prados, Ashley Margol, Cassie Kline, Sabine MuellerAbstract
Background
Embryonal tumor with multilayered rosettes (ETMR) is a rare, highly aggressive central nervous system embryonal tumor primarily affecting infants and young children, with poor outcomes despite intensive multimodality therapy. Retrospective data are limited by heterogeneous regimens and small cohorts, complicating reliable insights. To overcome these challenges, PNOC031 was developed through global collaboration among neuro-oncologists across continents (North America, Europe, Australia). This effort addresses inherent difficulties in designing trials for this rare tumor, tailoring treatments to individual patient needs, clarifying optimal timing and integration of radiotherapy and high-dose chemotherapy (HDC) with stem cell rescue, and establishing robust correlative studies with biomarkers for risk stratification and future therapy guidance.
Methods
This pragmatic, multi-cohort platform trial standardizes frontline care for newly diagnosed patients, including maximal safe resection, uniform IRS-III induction chemotherapy, and proactive intrathecal/intraventricular therapy. Radiation-eligible patients are randomized to early or late radiotherapy arms incorporating HDC where appropriate. Radiation-ineligible infants receive HDC-based therapy, while metastatic cases follow physician-directed regimens within trial backbones. Longitudinal biospecimens, neurocognitive/quality-of-life assessments, and outcomes are collected. The trial is currently opening and enrolling globally.
Aims
Primary: Independently evaluate 6-month progression-free survival (PFS) in each radiotherapy arm against historical radiation-sparing HDC controls. Secondary: Assess safety, feasibility, relapse patterns, and functional/quality-of-life outcomes across cohorts; correlate biomarkers with treatment response and relapse risk.
Correlative Studies
Comprehensive tumor analyses (whole-genome/exome seq, [single cell]RNA-seq, DNA methylation) and liquid biomarkers (e.g., circulating miR517a in blood/CSF) aim to identify genomic drivers, resistance mechanisms, and tools for real-time disease monitoring, early relapse detection, and risk-adapted therapeutic strategies.
Conclusions
PNOC031 exemplifies the strong commitment of global experts to collaboratively tackle complex clinical questions in rare pediatric cancers, generating standardized prospective data that fosters cross-trial aggregation and drives meaningful advancements toward personalized, effective care for this devastating disease.